Price Alert

Genmab A/S (GMAB)

NASDAQ: GMAB · Real-Time Price · USD

23.38

0.40 (1.74%)

At close: Aug 15, 2025, 12:23 PM

1.74% (1D)

Bid	16.81
Market Cap	14.75B
Revenue (ttm)	22.32B
Net Income (ttm)	6.71B
EPS (ttm)	1.93
PE Ratio (ttm)	12.11
Forward PE	1.61
Analyst	Buy

Ask	29.91
Volume	476,805
Avg. Volume (20D)	1,314,865.7
Open	23.36
Previous Close	22.98
Day's Range	23.35 - 23.49
52-Week Range	17.23 - 27.94
Beta	0.80

About GMAB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GMAB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Genmab A/S has released their quartely earnings on Aug 7, 2025:

Revenue of $925M misses estimates by $2.89B, with 18.66% YoY growth.

EPS of 0.542 exceeds estimates by 0.18, with 74.84% YoY growth.

Next Earnings Release

Genmab A/S is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+5.49%

Genmab shares are trading higher after the company... Unlock content with Pro Subscription

4 weeks ago

+3.4%

Genmab shares are trading higher after the company reported Q2 net sales of DARZALEX totaling $3.539B.

News

1 week ago · benzinga.com

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...

6 days ago · zacks.com

Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade

The mean of analysts' price targets for Genmab (GMAB) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

1 week ago · seekingalpha.com

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

Genmab A/S (GMAB) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Anthony Pagano - Executive VP & CFO Brad Bailey - Corporate Participant Jan G.J. van de Winkel - Co-F...

1 week ago · zacks.com

GMAB vs. ACAD: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks off...

1 week ago · youtube.com

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

1 week ago · youtube.com

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

3 weeks ago · zacks.com

Genmab (GMAB) Upgraded to Strong Buy: Here's Why

Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 weeks ago · zacks.com

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...

1 month ago · seekingalpha.com

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

Genmab A/S is a high-margin, royalty-driven biotech with a robust pipeline and strong partnerships, notably with J&J, AbbVie, and Pfizer. Darzalex remains the key revenue driver, but patent protection...

2 months ago · businesswire.com

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bisp...

Load More News